Edited by two experts working at the pioneering pharmaceutical company and major global player in hormone-derived drugs, this handbook and reference systematically treats the drug development aspects of all human nuclear receptors, including recently characterized receptors such as PPAR, FXR and LXR. Authors from leading pharmaceutical companies around the world present examples and real-life data from their own work.
İçerik tablosu
Nuclear Receptors as Modern Drug Targets – a Historic Perspective
Targeting the Nuclear Receptor – Cofactor Interaction
Untangling the Estrogen Receptor Web
Subtype Selective Estrogens
Estrogen Receptors as Therapeutic Targets in Breast Cancer
Progesterone Receptor and Progestines
Progesterone Receptor Antagonists
Nonsteroidal Tissue Selective Androgen Receptor Modulators
The Glucocorticoid Receptor as Target for Classic and Novel Anti-inflammatory Therapy and Novel Glucocorticoid Receptor Ligands
Vitamin D Analogs as Modulators of Vitamin D Receptor Action
PPARs: Therapeutic Targets for Metabolic Disease and Type 2 Diabetes
Retinoids in Clinical Use
Nuclear Receptors as Targets in Cardiovascular Diseases
NURR77 Family of Nuclear Receptors and its Modulators
Induction of Drug Metabolism: The Role of Nuclear Receptors
Nuclear Receptor Targeted Screening Libraries and Chemogenomics Approaches
Yazar hakkında
Eckard Ottow is the head of medicinal chemistry at Schering AG in Berlin (Germany). He studied Chemistry at the University of Hannover (Germany) and received his Ph D degree in 1982. He joined Schering AG in 1983, first in the field of endocrinology and later in oncology and CNS. In 2002, he was appointed to his present position as head of medicinal chemistry. He is also a honorary professor at the Technical University of Berlin.
Hilmar Weinmann studied Chemistry at the universities of Tübingen and Hannover (Germany). He joined Schering in 1995, where he is currently a department head of Medicinal Chemistry. His main fields of expertise are in oncology, dermatology and gender healthcare.